Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and ...
Morning Overview on MSN
A nasal spray reversed signs of brain aging in early tests, and a patent is already filed
Researchers at Texas A&M University reported that two intranasal doses of extracellular vesicles derived from human neural ...
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...
The gut microbiome is no longer viewed as a mere spectator in cancer development – it is increasingly recognized as a key ...
Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the ...
Newron Pharmaceuticals provides update following Type A meeting with the US FDA: Milan, Italy Saturday, July 4, 2026, 10:00 Hrs [IST] Newron Pharmaceuticals S.p.A. (Newron), a bio ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
FutureG Office is investing in cutting-edge, next-gen techIt has handed $28m in funding to Cohere Technologies for the ...
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...
Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results